Johan Baeck

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

John C. Byrd, Thomas J. Kipps, Ian W. Flinn et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2012 · 111 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

A phase 1 study of lucatumumab, a fully human anti‐<scp>CD</scp>40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

William Bensinger, Richard T. Maziarz, Sundar Jagannath et al. · British Journal of Haematology · 2012 · 108 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan et al. · Clinical Cancer Research · 2022 · 97 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase <scp>IA</scp>/<scp>II</scp>, multicentre, open‐label study of the <scp>CD</scp>40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐<scp>H</scp>odgkin or <scp>H</scp>odgkin lymphoma

Michelle A. Fanale, Sarit Assouline, John Kuruvilla et al. · British Journal of Haematology · 2013 · 77 citations · Full text

Medicine, Oncology, Pharmacology +15

Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)

Arnold S. Freedman, John Kuruvilla, Sarit Assouline et al. · Blood · 2010 · 15 citations

Medicine, Oncology, Pharmacology +16